Hantavirus Statistics in US 2026 | Symptoms, Treatment & Facts

What Is Hantavirus?

Hantavirus is a family of rodent-borne viruses capable of causing rare, severe, and frequently fatal disease in humans — and in 2026, it is the subject of more public attention than it has received in years. The disease first seized national consciousness in the United States in the spring of 1993, when an astute physician with the Indian Health Service noticed a disturbing cluster of deaths among young, previously healthy patients in the Four Corners region — the geographic intersection of Arizona, Colorado, New Mexico, and Utah. What investigators discovered was a previously unknown pathogen, subsequently named Sin Nombre virus (“virus with no name”), transmitted not person-to-person but through contact with the deer mouse (Peromyscus maniculatus), specifically through inhalation of microscopic particles from the animal’s urine, droppings, or saliva. That 1993 outbreak killed half of the people it infected and launched three decades of federal surveillance, scientific research, and public health education that continues to this day. Hantaviruses cause two distinct clinical syndromes: Hantavirus Pulmonary Syndrome (HPS), the primary form in the Americas, which attacks the lungs and cardiovascular system, and Hemorrhagic Fever with Renal Syndrome (HFRS), more common in Europe and Asia, which targets the kidneys. In the United States, it is HPS — and its terrifying capacity to turn an apparent flu into fatal respiratory failure within days — that defines the public health threat.

2026 has thrust hantavirus back into global headlines with unusual force. Domestically, the high-profile death of Betsy Arakawa, wife of late actor Gene Hackman, from HPS in their Santa Fe, New Mexico home in early 2025 brought the disease’s ongoing presence in endemic communities to national attention for the first time in years. Internationally, a suspected hantavirus cluster aboard the Dutch cruise ship MV Hondius, traveling from Argentina to Cape Verde in the Atlantic, resulted in three deaths and at least one laboratory-confirmed case as of May 4, 2026 — an extraordinary occurrence given that hantavirus is almost never associated with maritime environments, prompting immediate WHO investigation and worldwide media coverage. Against this backdrop, the CDC’s most current surveillance data — updated as recently as April 23, 2026 — documents 890 laboratory-confirmed hantavirus disease cases in the United States since surveillance began in 1993 through the end of 2023, with additional cases recorded in 2024 and 2025 from Arizona, Colorado, New Mexico, Washington, California, Louisiana, and other states. The numbers are small by the scale of most infectious diseases. The lethality is not.

Hantavirus Key Facts at a Glance | US 2026

Data Source: CDC, “Reported Cases of Hantavirus Disease,” updated April 23, 2026 (cdc.gov/hantavirus); CDC, “About Hantavirus,” updated 2026; PAHO Hantavirus in the Americas 2025 report (December 31, 2025); Box-Kat, “Cases of Hantavirus by State 2026 Updates” (citing CDC NNDSS data); New Mexico Department of Health, HPS surveillance data (1975–2025); University of Arizona Cooperative Extension, Hantavirus and Disease Prevention (August 2025); PBS NewsHour, May 4, 2026; CNN, May 4–5, 2026; WHO statement May 4–5, 2026

The 890 laboratory-confirmed hantavirus cases in the United States since 1993 may seem modest against a backdrop of diseases that infect millions annually — but the numbers are deeply misleading as a guide to severity. A disease with a 35–38% overall fatality rate is not a minor public health footnote; it is one of the deadliest infectious diseases endemic to North American soil. For comparison, seasonal influenza kills less than 0.1% of those infected; COVID-19 in its most lethal waves killed roughly 1–3%; Ebola kills approximately 50–70% in major outbreaks. HPS sits between COVID-19 and Ebola on the lethality spectrum — and it does so with no specific antiviral treatment, no approved vaccine, and no person-to-person transmission to trigger the kind of broad public health emergency response that would generate the funding and infrastructure that faster-spreading diseases attract. The 38% of HPS patients who develop respiratory symptoms and die represent a fraction of overall exposures — because many people exposed to hantavirus-infected rodent material either never develop symptoms or recover during the early, flu-like phase — but for those who progress to the cardiopulmonary stage, the clinical picture deteriorates with terrifying speed.

The geographic concentration of US cases is one of the most consistent findings in three decades of surveillance data. As of the end of 2023, 890 cases of hantavirus disease had been reported in the United States since surveillance began in 1993, all laboratory-confirmed and including HPS and non-pulmonary hantavirus infections. A vast majority — 94 percent — of those cases have come west of the Mississippi River. The Four Corners region is the epicenter of this geographic concentration, and understanding why requires understanding the ecology of the deer mouse — a species whose population fluctuates dramatically with rainfall and food availability. In years following heavy precipitation (which stimulates plant growth, which produces seeds, which feeds rodents), deer mouse populations explode, increasing both the density of potentially infected animals and the probability of human–rodent contact. This ecological trigger explains why hantavirus case counts tend to cluster in spikes — the 2012 Yosemite outbreak, the 2023–2024 Arizona spike, and the current attention on New Mexico all trace back to environmental conditions that drove rodent population surges in preceding seasons.

Hantavirus Cases in the US 2026 | Historical Data & State Breakdown

Data Source: CDC, “Reported Cases of Hantavirus Disease,” April 23, 2026 (cdc.gov/hantavirus/data-research/cases); Box-Kat, “Cases of Hantavirus by State 2026 Updates” (citing CDC NNDSS data); PAHO Hantavirus Americas Report December 31, 2025; New Mexico Dept. of Health HPS surveillance page (1975–2025); University of Arizona Cooperative Extension (August 2025)

Hantavirus disease surveillance in the United States began in 1993 during an outbreak of severe respiratory illness in the Four Corners region — the area where Arizona, Colorado, New Mexico, and Utah meet. The cumulative state breakdown reveals a remarkably durable geographic pattern: New Mexico and Colorado have traded the top two positions across three decades of data, each accumulating over 119 cases since 1993, while Arizona has surged in recent years, leading all states with 26 confirmed cases in the most recent five-year period (2020–2025). Arizona’s recent surge tracks directly with documented environmental triggers: the state experienced a significant above-average monsoon season in 2022–2023, driving a deer mouse population explosion in the high-desert and piñon-juniper ecosystems that span northern Arizona and into the Four Corners. The University of Arizona Cooperative Extension documented 6 confirmed cases in Arizona in 2023 and 11 in 2024 — a case count that dramatically exceeded the state’s recent historical baseline of 1–3 per year.

The 2025 data from the Pan American Health Organization (PAHO), which tracks hantavirus across all Americas countries, is the most granular recent snapshot available for the United States at the national level. The United States reported seven confirmed cases and two deaths — a case fatality rate of 29% — in the following states: Arizona (n=3), Colorado (n=1), Nevada (n=1), Washington (n=1), and Wisconsin (n=1). The appearance of Wisconsin and Nevada on the 2025 confirmed case list is noteworthy — both are states with relatively low historical case counts, and their 2025 cases serve as a reminder that hantavirus risk in the United States is not strictly a Southwest phenomenon. The Louisiana 2025 cases, involving the Bayou virus rather than Sin Nombre virus, further underscore this point: two unrelated cases of HPS caused by the Bayou virus were reported in Louisiana — one patient died, and the other required intensive care; genetic sequencing indicated that these were separate spillover events from rodents, highlighting the virus’s presence in the southeastern U.S.

Hantavirus Symptoms 2026 | Early & Late Stage Clinical Signs

Data Source: CDC, “About Hantavirus,” updated 2026 (cdc.gov/hantavirus/about); CDC, “Hantavirus Pulmonary Syndrome — Clinical Overview for Health Providers” (2026); PMC — “Twenty-Year Summary of Surveillance for Human Hantavirus Infections” (NIH/NCBI); PBS NewsHour, May 4, 2026; CNN Hantavirus explainer, May 4, 2026

The clinical progression of HPS is among the most terrifying features of this disease — not because symptoms are unusual, but because they are profoundly ordinary at first. Symptoms of HPS usually start to show 1 to 8 weeks after contact with an infected rodent; early symptoms include muscle aches especially in the large muscle groups like the thighs, hips, back, and sometimes shoulders. That symptom profile — fever, fatigue, muscle pain, headache — overlaps almost perfectly with influenza, making early clinical differentiation extremely difficult. The critical differentiating clue is what is absent: unlike influenza and common colds, HPS does not produce a runny nose, sore throat, or productive cough in its early stages. Clinicians familiar with hantavirus risk areas have learned to treat a patient presenting with flu-like illness and intense muscle aches in the large muscle groups — particularly with a history of possible rodent exposure — as a potential hantavirus case until proven otherwise. Diagnosing hantavirus in a person who has been infected less than 72 hours is difficult; early symptoms such as fever, headache, muscle aches, nausea, and fatigue are easily confused with influenza.

What transforms HPS from severe illness into frequently fatal crisis is the cardiopulmonary transition. Four to 10 days after the initial phase of illness, the late symptoms of HPS appear: coughing, shortness of breath, and tightness in the chest, as the lungs fill with fluid. This fluid accumulation — called non-cardiogenic pulmonary edema — reflects immune-mediated damage to the tiny blood vessels of the lung, causing them to leak plasma into the alveolar spaces where gas exchange normally occurs. Simultaneously, the virus-induced immune response drives a form of cardiogenic shock — the heart itself fails to pump adequately, blood pressure drops, and multiple organ systems begin to deteriorate in cascade. Patients can go from walking into an emergency room with a “bad flu” to requiring mechanical ventilation within 24–48 hours. This speed of progression is why the single most important public health message around hantavirus has never changed: if you have had rodent exposure and develop fever and muscle aches, do not wait to see if symptoms improve. Tell every healthcare provider about the rodent exposure, and seek care immediately.

Hantavirus Treatment in the US 2026 | Medical Management

Data Source: CDC, “About Hantavirus — Treatment” (cdc.gov/hantavirus/about, updated 2026); PBS NewsHour, “What to Know About Hantavirus,” May 4, 2026; CNN Hantavirus explainer, May 4–5, 2026; PMC — “Twenty-Year Summary of Surveillance for Human Hantavirus Infections” (NCBI); UNM Health Sciences Center / Dr. Michelle Harkins (PBS NewsHour citation, May 2026)

There is no specific treatment for hantavirus infection; patients should receive supportive care, including rest, hydration, and treatment of symptoms. HPS can cause breathing difficulties, and patients may need breathing support such as intubation — a medical procedure where a tube is placed in the lungs from the mouth to help the patient get oxygen. HFRS can disrupt kidney function, and patients with HFRS may need dialysis to remove toxins from the blood and maintain the right balance of fluids in the body when the kidneys aren’t working well. The absence of a specific antiviral treatment for HPS — despite three decades of research — reflects the biological challenges of developing therapies for a virus that kills through the immune system’s own overreaction rather than direct tissue destruction. Ribavirin, an antiviral drug used against other hemorrhagic fever viruses, has been studied extensively for hantavirus and shown some promise in laboratory settings, but controlled clinical trials have not demonstrated a survival benefit for HPS patients treated with ribavirin compared to supportive care alone. It remains in use in some countries for HFRS management, but it is not approved or recommended for HPS in the United States. The most important clinical intervention remains the speed and quality of the supportive care: patients transferred to ICU-level care early, managed by teams experienced in ARDS and cardiogenic shock, have meaningfully better outcomes than those who present late or are managed in facilities without critical care expertise.

Despite years of research, many questions have yet to be answered, including why HPS can be mild for some people and very severe for others and how antibodies are developed. This unpredictability in clinical outcomes — patients with apparently similar exposures and similar initial presentations ending up with dramatically different outcomes — is one of the most frustrating features of HPS for both clinicians and researchers. It suggests that individual immune genetics, viral dose at time of exposure, and possibly specific strain characteristics of the infecting virus all play roles in determining whether a patient recovers from the prodromal phase or progresses to fulminant cardiopulmonary failure. The University of New Mexico Health Sciences Center, which has managed more HPS patients than almost any other institution in the country given New Mexico’s consistently high case burden, has been following long-term cohorts of survivors for years in an attempt to understand both the pathogenesis of severe disease and the long-term effects of HPS on pulmonary function in those who recover — a research program that represents perhaps the most sustained single-institution effort to crack the clinical mysteries of this disease.

Hantavirus Transmission & Prevention in the US 2026

Data Source: CDC, “About Hantavirus — Prevention” (cdc.gov/hantavirus/about, updated 2026); CDC Hantavirus Fact Sheet (2026); CNN Hantavirus explainer, May 4–5, 2026; PBS NewsHour, May 4, 2026; University of Arizona Cooperative Extension, Hantavirus and Disease Prevention (August 2025)

People get hantavirus from contact with rodents like rats and mice, especially when exposed to their urine, droppings, and saliva; it can also spread through a bite or scratch by a rodent, but this is rare. The mechanics of transmission explain why certain activities carry dramatically higher risk than others: disturbing accumulated rodent material in an enclosed space with poor ventilation is the single highest-risk scenario in all of hantavirus epidemiology. When a person enters a cabin, storage shed, barn, or vehicle that has been inhabited by rodents and begins cleaning — particularly by sweeping or using a vacuum — the dried rodent material becomes airborne in microscopic particles that are invisible to the naked eye and that can deliver enough viral particles to initiate infection with a single breath. This is why the CDC’s cleanup protocol is so specific and so non-negotiable: spray first with bleach solution, wait five minutes, then wipe with a damp cloth — never sweep, never vacuum, always wear an N95 respirator and rubber gloves. The best way to avoid the germ is to minimize contact with rodents and their droppings; use protective gloves and a bleach solution for cleaning up rodent droppings.

The person-to-person transmission question is one of the most important practical distinctions in understanding hantavirus public health risk — and it is particularly relevant in the context of the May 2026 MV Hondius cruise ship cluster. In North America, including the United States, hantavirus is unambiguously not spread from person to person. Only one hantavirus — the Andes strain, native to South America — is known to have spread from person-to-person, and this is rare. The cruise ship traveling from Argentina was thus operating in a region where the Andes virus, the only hantavirus with documented person-to-person spread, is endemic — a critical epidemiological detail that differentiates the Atlantic outbreak from the standard US risk profile. Investigators have detected the virus in one passenger, but that individual remains alive; so far, none of the three deaths has had confirmed links to hantavirus, but we are awaiting more information. The WHO assessed the risk to the wider public as low and recommended no mass public alarm — a measured assessment consistent with hantavirus’s historical behavior even in clusters, which have never produced epidemic-scale spread outside of controlled outbreak settings.

Hantavirus 2026 | Notable US Cases & Current Developments

Data Source: CDC “Reported Cases of Hantavirus Disease” (April 23, 2026); New Mexico Dept. of Health HPS surveillance; PAHO Hantavirus Americas Report (December 31, 2025); Box-Kat citing CDC NNDSS (2026 update); PBS NewsHour May 4, 2026; CNN May 4–5, 2026; WHO statement May 4–5, 2026; Jeremy Faust MD, Inside Medicine May 4, 2026

The Betsy Arakawa case in February 2025 served as a stark reminder that hantavirus risk in endemic areas is not confined to high-risk occupational or recreational activities. Arakawa, wife of late actor Gene Hackman, died from HPS at their Santa Fe, New Mexico home — a death that generated more national media attention around hantavirus than any single case since the 2012 Yosemite outbreak. Her death brought national attention to the dangers of hantavirus, especially in areas where the virus is endemic. The Mono County, California 2024 cluster of three fatal HPS cases — including a 26-year-old hotel employee — was similarly alarming because, as the Box-Kat report noted, health officials noted that none of the victims had engaged in typical high-risk activities, suggesting possible exposure during routine daily activities. These cases challenge the comfortable assumption that hantavirus is primarily a risk for campers cleaning out mountain cabins or agricultural workers handling grain stores — in endemic communities of the Southwest, exposure can occur in ordinary residential and occupational settings.

The University of New Mexico research finding that over 30 small mammal species in New Mexico carry live hantavirus, including ground squirrels and chipmunks, is one of the most significant recent developments in US hantavirus science. For three decades, public health messaging has focused almost exclusively on the deer mouse as the primary reservoir — a messaging strategy that was accurate in its emphasis on the most common transmission source but potentially misleading in implying that avoiding deer mice is sufficient protection. A reservoir that spans 30+ species across the rodent and small mammal community represents a fundamentally harder target for prevention messaging and a broader ecological web of potential human exposure. This finding suggests a broader range of potential carriers beyond the commonly known deer mouse. The January 2026 detection of hantavirus in a Western harvest mouse in San Diego County — a species not previously prominent in US hantavirus surveillance — is consistent with this expanded reservoir picture and may foreshadow a shift in how CDC surveillance is structured in the years ahead.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE